Compare AROW & RGNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AROW | RGNX |
|---|---|---|
| Founded | 1851 | 2008 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 727.1M | 793.5M |
| IPO Year | 1995 | 2015 |
| Metric | AROW | RGNX |
|---|---|---|
| Price | $38.30 | $9.37 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 8 |
| Target Price | $28.00 | ★ $28.75 |
| AVG Volume (30 Days) | 72.6K | ★ 1.2M |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | ★ 3.33% | N/A |
| EPS Growth | ★ 49.72 | 18.08 |
| EPS | ★ 1.48 | N/A |
| Revenue | N/A | ★ $10,393,000.00 |
| Revenue This Year | $33.36 | $51.21 |
| Revenue Next Year | $18.26 | $19.08 |
| P/E Ratio | $25.71 | ★ N/A |
| Revenue Growth | N/A | ★ 126.48 |
| 52 Week Low | $25.91 | $5.46 |
| 52 Week High | $42.70 | $16.19 |
| Indicator | AROW | RGNX |
|---|---|---|
| Relative Strength Index (RSI) | 39.23 | 42.90 |
| Support Level | $37.23 | $7.95 |
| Resistance Level | $40.29 | $9.67 |
| Average True Range (ATR) | 0.80 | 0.69 |
| MACD | -0.09 | -0.21 |
| Stochastic Oscillator | 46.45 | 33.18 |
Arrow Financial Corp is a holding company. It provides various advisory and administrative services and coordinates the general policies and operations of the banks. It provides financial products, including online and mobile banking, mortgages, commercial loans, investments, and others. The company also provides lending services, including commercial and industrial lending to small and mid-sized companies; mortgage lending for residential and commercial properties; and consumer installment and home equity financing. The key source of the company's revenue is interest income, fees, commission earned through its subsidiaries.
Regenxbio Inc is a clinical-stage biotechnology company focused on the development of gene therapy treatments. Its product candidates are designed to deliver genes to cells to address genetic defects or enable the production of therapeutic proteins. The company is developing a pipeline of investigational gene therapy treatments using its NAV Technology Platform based on adeno-associated virus (AAV) vectors. Its internal research and development programs are focused on therapies for retinal, neuromuscular, and neurodegenerative diseases.